3Jone SG. Taking HAART: How to support patients with HIV/ AIDS[J]. Nursing,2001,31(12) :36 - 41.
4Crum NF,Riffenburgh RH,Wegner S,et al.Comparisons of causesof death and mortality rates among HIV-infected persons:anal-ysis of the pre-,early,and late HAART(highly active antiretro-viral therapy)eras[J].J Acquir Immune Defic Syndr,2006,41(2):194-200.
5Bangsberg DR.Less than 95% adherence to nonnucleoside re-verse-transcriptase inhibitor therapy can lead to viral suppres-sion[J],Clinical Infectious Diseases,2006,43(7):939-941.
6Shuter J.Forgiveness of non-adherence to HIV-1 antiretroviraltherapy[J].J Antimicrob Chemother,2008,61(4)-.769-773.
8Oyugi JH,Byakika-Tusiime J,Ragland K,et al.Treatment in-terruptions predict resistance in HIV-positive individuals pur-chasing fixed-dose combination antiretroviral therapy in Kam-pala,Uganda[J].AIDS,2007,21(8):965-971.
9Quinn TC,Wawer MJ,Sewankambo N,et al.Viral load andheterosexual transmission of human immunodeficiency virustype 1[J].New England Journal of Medicine,2000,342(13);921-929.
10Ickovics JR,Meisler AW.Adherence in AIDS clinical trials:aframework for clinical research and clinical care[J].J Clin Epi-demiol,1997,50(4):385-391.
